Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, highlighted the importance of scientific research during his May 31 remarks at the 2017 FDA Science Forum.
Commissioner Gottlieb stated that promoting creativity and efficiency, attracting top-quality scientists, and allowing them to conduct cutting-edge research are among his highest priorities. He noted that a major challenge in protecting public health is the increasing diversity and sophistication of new products.
He added that risks with novel approaches, such as gene therapy and gene editing, are a continued interest of the FDA. The FDA is formulating new guidance concerning regenerative medicine and seeks to advance standards in these areas to help move products forward.